Related Experiment Video
Updated: Jun 27, 2026
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
Therapy-Related Leukemia following Docetaxel Chemotherapy for Metastatic Hormone-Sensitive Prostate Cancer: A Case
Chen Zhu1, Jian Su1, Zhenhua Jin2
1Department of Urology, Jiangsu Province Hospital of Chinese Medicine, Nanjing, China.
Introduction:
Docetaxel is the first-line drug that has been proved to improve the overall survival of men with metastatic hormone-sensitive prostate cancer (mHSPC). For patients who survive the prostate cancer, they may be at risk of secondary neoplasm, especially for the therapy-related myelodysplastic syndrome or therapy-related acute myeloid leukemia (t-AML).
Case Presentation:
We reported a 44-year-old man with prostate cancer (cT4N1M1c) who developed t-AML following docetaxel chemotherapy. Typically, the t-AML in our case was characterized by an aberrant karyotype t(15;17)(q22;q21).
Conclusions:
This case is, to our knowledge, the first time to report a patient with mHSPC who developed therapy-related acute promyelocytic leukemia following docetaxel chemotherapy, suggesting that docetaxel might contribute to the induction of t-AML.
More Related Videos
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...